MAP2K1 and neoplasm: A recent chemogenomic screen identified strong synergy between FAK and mitogen-activated protein kinase 1/2 (MEK1/2) inhibition, particularly trametinib, suppressing invasion and tumor burden across heterogeneous stem cell models (43).